How I treat Langerhans cell histiocytosis

• Published in: Blood Vol. 126; no. 1; pp. 26 - 35
• Main Authors: Allen, Carl E., Ladisch, Stephan, McClain, Kenneth L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 02.07.2015; American Society of Hematology
• Subjects: Adenine Nucleotides - therapeutic use; Adult; Arabinonucleosides - therapeutic use; Clofarabine; Cytarabine - therapeutic use; Female; Histiocytosis, Langerhans-Cell - pathology; Histiocytosis, Langerhans-Cell - therapy; How I Treat; Humans; Infant; Infant, Newborn; Lung Diseases - therapy; Male; Middle Aged; Remission Induction; Skin Diseases - therapy; Thoracic Surgery, Video-Assisted; Vaginal Diseases - therapy
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2014-12-569301

“Langerhans cell histiocytosis” (LCH) describes a spectrum of clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease. Regardless of clinical severity, LCH lesions share the common histology of CD1a+/CD207+ dendritic cells with characteristic morphology among an inflammatory infiltrate. Despite historical uncertainty defining LCH as inflammatory vs neoplastic and incomplete understanding of mechanisms of pathogenesis, clinical outcomes have improved markedly over the past decades through cooperative randomized clinical trials based on empiric therapeutic strategies. Significant advances include recognition of high- and low-risk clinical groups defined by hematopoietic and/or hepatic involvement, and of the importance of optimal intensity and of duration of chemotherapy. Nevertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage strategies, and significant disease morbidity of both high- and low-risk patients remain challenges. Recent discovery of recurrent somatic mutations in mitogen-activated protein kinase pathway genes at critical stages of myeloid hematopoietic differentiation in LCH patients supports redefinition of the disease as a myeloproliferative disorder and provides opportunities to develop novel approaches to diagnosis and therapy.